HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Urinary Bladder Neck Obstruction (Bladder Neck Obstruction)

Blocked urine flow through the bladder neck, the narrow internal urethral opening at the base of the URINARY BLADDER. Narrowing or strictures of the URETHRA can be congenital or acquired. It is often observed in males with enlarged PROSTATE glands.
Also Known As:
Bladder Neck Obstruction; Bladder Outlet Obstruction
Networked: 1308 relevant articles (116 outcomes, 180 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
2. Lower Urinary Tract Symptoms
3. Prostatic Neoplasms (Prostate Cancer)
4. Overactive Urinary Bladder (Overactive Bladder)
5. Fibrosis (Cirrhosis)

Experts

1. Levin, Robert M: 17 articles (11/2014 - 03/2002)
2. Chacko, Samuel: 15 articles (03/2013 - 06/2002)
3. Wein, Alan J: 14 articles (10/2015 - 06/2002)
4. Kim, Joon Chul: 13 articles (02/2022 - 10/2004)
5. Zderic, Stephen A: 13 articles (03/2013 - 06/2002)
6. Kuo, Hann-Chorng: 11 articles (01/2022 - 05/2004)
7. Funahashi, Yasuhito: 11 articles (12/2020 - 01/2013)
8. Gotoh, Momokazu: 11 articles (12/2020 - 01/2013)
9. Matsukawa, Yoshihisa: 11 articles (12/2020 - 01/2013)
10. Kaplan, Steven A: 10 articles (10/2021 - 07/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Urinary Bladder Neck Obstruction:
1. silodosinFDA Link
01/01/2017 - "The magnitude of bladder outlet obstruction improvement in patients receiving silodosin is higher if compared to other ABs. "
12/01/2014 - "The pressure flow studies demonstrated that silodosin had significantly enlarged the bladder capacity when the first non-voiding contraction was seen at 3 and 12 months (3M: 127.1 ± 74.8 vs. 118.2 ± 83.9 mL, p = 0.001; 12M: 123.7 ± 79.3 vs. 100.3 ± 73.4 mL, p = 0.01); however, there were no improvements in the bladder outlet obstruction index (BOOI) or urinary flow. "
03/01/2018 - "A significant decrease in bladder outlet obstruction index was observed with silodosin reception (Urorec®) 8 mg once daily (-28.8 [95% CI: -28.2, -29.5] or -44.5% [95% CI: -43.4%, - 45.5%] (p <0.001)), a decrease in IPSS scores after 30, 60 and 120 days from initiation of treatment (-6.3 [95% CI: -5.9, -6.7], -6.5 [95% CI: -6.1, - 6.9], -6.8 [95% CI: -6.4, -7.2] respectively (p <0.001)), an increase in Qmax after 7, 14, 30, 60 and 120 days from initiation of treatment (+1.1 mL/s [95% CI: 1.0 mL/s, 1.2 mL/s], +1.6 mL/s [95% CI: 1.5 mL/s, 1.7 mL/s], +2.4 mL/s [95% CI: 2.3 mL/s, 2.5 mL/s], +2.5 mL/s [95% CI: 2.4 mL/s, 2.6 mL/s], +2.5 mL/s [95% CI: 2.4 mL/s, 2.7 mL/s] respectively (p <0.001)). "
01/01/2018 - "We investigated the effects of silodosin, an α1A-adrenoceptor (AR) antagonist, on bladder function, especially on non-voiding contractions (NVCs), in a male rat model of bladder outlet obstruction (BOO) by evaluating cystometry (CMG) findings and bladder mechanosensitive single-unit afferent activities (SAAs), related with microcontractions, which may be similar with NVCs and to be of myogenic origin, in the rat model. "
01/01/2018 - "Inhibitory effects of silodosin on the bladder mechanosensitive afferent activities and their relation with bladder myogenic contractions in male rats with bladder outlet obstruction."
2. Tamsulosin (Flomax)FDA LinkGeneric
3. Cholinergic Antagonists (Anticholinergics)IBA
4. Muscarinic AntagonistsIBA
5. Terazosin (Hytrin)FDA LinkGeneric
6. Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA
7. Finasteride (Propecia)FDA LinkGeneric
8. CollagenIBA
9. Tadalafil (Cialis)FDA Link
01/01/2013 - "Urodynamic measures remained largely unchanged during the study with no statistically significant or clinically adverse difference between tadalafil and placebo in change in detrusor pressure at maximum urinary flow rate (mean difference between treatments -2.2 cm H(2)O, p = 0.33) or any other urodynamic parameter assessed including maximum urinary flow rate, maximum detrusor pressure, bladder outlet obstruction index or bladder capacity (all measures p ≥0.13). "
03/01/2010 - "Urodynamic measures remained largely unchanged during the study with no statistically significant or clinically adverse difference between tadalafil and placebo in change in detrusor pressure at maximum urinary flow rate (mean difference between treatments -2.2 cm H(2)O, p = 0.33) or any other urodynamic parameter assessed including maximum urinary flow rate, maximum detrusor pressure, bladder outlet obstruction index or bladder capacity (all measures p > or = 0.13). "
01/01/2020 - "Long-term tadalafil administration can prevent functional and structural changes of the urinary bladder in male rats with partial bladder outlet obstruction."
01/01/2018 - "Treatment with tadalafil 5 mg once daily effectively relieves lower urinary tract symptoms based on objective improvement of storage and voiding function, such as detrusor overactivity and bladder outlet obstruction, in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia."
01/01/2013 - "We conducted a multicenter, randomized, double blind, placebo controlled clinical trial comparing once daily tadalafil 20 mg vs placebo during 12 weeks in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia with or without bladder outlet obstruction. "
10. NeodymiumIBA

Therapies and Procedures

1. Transurethral Resection of Prostate (TURP)
2. Solid-State Lasers
3. Prostatectomy (Retropubic Prostatectomy)
4. Therapeutics
5. Lasers (Laser)